• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用常规临床和预处理存档对非小细胞肺癌中22C3和SP263 PD-L1表达的综合比较

Comprehensive Comparison of 22C3 and SP263 PD-L1 Expression in Non-Small-Cell Lung Cancer Using Routine Clinical and Conditioned Archives.

作者信息

Kim Sue Youn, Kim Tae-Eun, Park Chan Kwon, Yoon Hyoung-Kyu, Sa Young Jo, Kim Hyo Rim, Woo In Sook, Kim Tae-Jung

机构信息

Department of Hospital Pathology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea.

Department of Hospital Pathology, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, 10, 63-ro, Yeongdeungpo-gu, Seoul 07345, Korea.

出版信息

Cancers (Basel). 2022 Jun 27;14(13):3138. doi: 10.3390/cancers14133138.

DOI:10.3390/cancers14133138
PMID:35804910
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9265108/
Abstract

PD-L1 harmonization studies revealed a strong correlation between the 22C3 and SP263 assays in non-small-cell lung cancer (NSCLC). However, the assays’ characteristics have yet to be validated in a variety of clinical and analytical settings. The results of 431 NSCLC samples tested concurrently in routine clinical practice with the PD-L1 22C3 and SP263 assays were reviewed, and both assays were performed on 314 archives of surgically resected NSCLCs to assess PD-L1 expression in relation to variables such as FFPE block age and FFPE section storage condition. In routine clinical samples, 22C3 showed the highest concordance rate with 94.5% of SP263 tumor proportion score (TPS) ≥50% and 92.3% of SP263 TPS ≥1%, while SP263 showed a concordance rate with 79.6% of 22C3 TPS ≥50% and 89.9% of 22C3 TPS ≥1%. In the archival analysis, the high TPS of 22C3 and SP263 (versus TPS 1%) were significantly associated with a more recent block (<3 years versus ≥3 years) (p = 0.007 and p = 0.009, respectively). Only the TPS of 22C3 was reduced when FFPE sections were stored at room temperature compared to SP263. However, when stored at 4 °C, the storage duration had no effect on expression in either assay. For 22C3 TPS 1−49 percent and ≥50 percent (OR = 1.73, p = 0.006 and OR = 1.98, p = 0.002, respectively). There was a considerably larger chance of preserved 22C3 expression in recent room-temperature paraffin section storage, although SP263 demonstrated preserved expression in prolonged room-temperature section storage. Despite the good association between PD-L1 22C3 and SP263 in routine clinical samples, FFPE blocks older than 3 years and sections held at room temperature for more than 1 week may result in an underestimation of PD-L1 status, particularly for the 22C3 test. However, the SP263 assay was more sensitive under these conditions.

摘要

PD-L1一致性研究显示,在非小细胞肺癌(NSCLC)中,22C3检测法与SP263检测法之间存在强相关性。然而,这些检测法的特性尚未在各种临床和分析环境中得到验证。回顾了在常规临床实践中同时使用PD-L1 22C3和SP263检测法检测的431例NSCLC样本的结果,并对314例手术切除的NSCLC存档样本进行了这两种检测,以评估PD-L1表达与诸如FFPE组织块保存年限和FFPE切片保存条件等变量的关系。在常规临床样本中,22C3与SP263肿瘤比例评分(TPS)≥50%的一致性率最高,为94.5%,与SP263 TPS≥1%的一致性率为92.3%,而SP263与22C3 TPS≥50%的一致性率为79.6%,与22C3 TPS≥1%的一致性率为89.9%。在存档分析中,22C3和SP263的高TPS(相对于TPS 1%)与更新的组织块(<3年对比≥3年)显著相关(分别为p = 0.007和p = 0.009)。与SP263相比,当FFPE切片在室温下保存时,只有22C3的TPS降低。然而,当在4℃保存时,保存时长对两种检测法的表达均无影响。对于22C3 TPS为1%-49%和≥50%的情况(OR分别为 = 1.73,p = 0.006和OR = 1.98,p = 0.002)。在近期室温石蜡切片保存中,22C3表达保留的可能性要大得多,尽管SP263在长时间室温切片保存中显示出表达保留。尽管在常规临床样本中PD-L1 22C3与SP263之间具有良好的相关性,但保存年限超过3年的FFPE组织块以及在室温下保存超过1周的切片可能会导致PD-L1状态被低估,尤其是对于22C3检测。然而,在这些条件下,SP263检测法更敏感。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b731/9265108/bae3823f3db6/cancers-14-03138-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b731/9265108/38995182c188/cancers-14-03138-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b731/9265108/e5488e2d23d1/cancers-14-03138-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b731/9265108/54a52bec6d12/cancers-14-03138-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b731/9265108/bae3823f3db6/cancers-14-03138-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b731/9265108/38995182c188/cancers-14-03138-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b731/9265108/e5488e2d23d1/cancers-14-03138-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b731/9265108/54a52bec6d12/cancers-14-03138-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b731/9265108/bae3823f3db6/cancers-14-03138-g004.jpg

相似文献

1
Comprehensive Comparison of 22C3 and SP263 PD-L1 Expression in Non-Small-Cell Lung Cancer Using Routine Clinical and Conditioned Archives.使用常规临床和预处理存档对非小细胞肺癌中22C3和SP263 PD-L1表达的综合比较
Cancers (Basel). 2022 Jun 27;14(13):3138. doi: 10.3390/cancers14133138.
2
Comparison of SP263 and 22C3 immunohistochemistry PD-L1 assays for clinical efficacy of adjuvant atezolizumab in non-small cell lung cancer: results from the randomized phase III IMpower010 trial.SP263 和 22C3 免疫组化 PD-L1 检测在非小细胞肺癌辅助阿特珠单抗治疗中的临床疗效比较:来自随机 III 期 IMpower010 试验的结果。
J Immunother Cancer. 2023 Oct;11(10). doi: 10.1136/jitc-2023-007047.
3
Comparison of SP263 and 22C3 pharmDx assays to test programmed death ligand-1 (PD-L1) expression in surgically resected non-small cell lung cancer.比较SP263和22C3免疫组化检测法在手术切除的非小细胞肺癌中检测程序性死亡配体-1(PD-L1)表达的情况。
Thorac Cancer. 2024 Jun;15(17):1343-1349. doi: 10.1111/1759-7714.15319. Epub 2024 May 3.
4
Predictive Performance of Four Programmed Cell Death Ligand 1 Assay Systems on Nivolumab Response in Previously Treated Patients with Non-Small Cell Lung Cancer.四种程序性死亡配体 1 检测系统在先前治疗的非小细胞肺癌患者对纳武利尤单抗反应中的预测性能。
J Thorac Oncol. 2018 Mar;13(3):377-386. doi: 10.1016/j.jtho.2017.11.123. Epub 2017 Dec 9.
5
PD-L1 immunohistochemical expression in bladder urothelial cancer with SP263, SP142 and 22C3 antibodies: A comparative study.使用SP263、SP142和22C3抗体检测膀胱尿路上皮癌中PD-L1的免疫组化表达:一项比较研究。
Ann Diagn Pathol. 2024 Apr;69:152267. doi: 10.1016/j.anndiagpath.2024.152267. Epub 2024 Jan 20.
6
The Ring Study: an international comparison of PD-L1 diagnostic assays and their interpretation in non-small cell lung cancer, head and neck squamous cell cancer and urothelial cancer.环研究:非小细胞肺癌、头颈部鳞状细胞癌和尿路上皮癌中PD-L1诊断检测及其解读的国际比较
Pathology. 2023 Feb;55(1):19-30. doi: 10.1016/j.pathol.2022.07.016. Epub 2022 Oct 1.
7
Inter-tumor heterogeneity of PD-L1 expression in non-small cell lung cancer.非小细胞肺癌中PD-L1表达的肿瘤间异质性。
J Thorac Dis. 2019 Dec;11(12):4982-4991. doi: 10.21037/jtd.2019.12.24.
8
PD-L1 expression in non-small cell lung cancer: evaluation of the diagnostic accuracy of a laboratory-developed test using clone E1L3N in comparison with 22C3 and SP263 assays.PD-L1 表达在非小细胞肺癌中的应用:使用 E1L3N 克隆与 22C3 和 SP263 检测试剂盒比较评估实验室开发检测试剂盒的诊断准确性。
Hum Pathol. 2019 Aug;90:54-59. doi: 10.1016/j.humpath.2019.05.003. Epub 2019 May 21.
9
CT-guided transthoracic needle biopsy for evaluation of PD-L1 expression: Comparison of 22C3 and SP263 assays.CT 引导下经胸穿刺活检评估 PD-L1 表达:22C3 与 SP263 检测方法的比较。
Thorac Cancer. 2019 Jul;10(7):1612-1618. doi: 10.1111/1759-7714.13126. Epub 2019 Jun 24.
10
Multicenter Comparison of 22C3 PharmDx (Agilent) and SP263 (Ventana) Assays to Test PD-L1 Expression for NSCLC Patients to Be Treated with Immune Checkpoint Inhibitors.多中心比较 22C3 PharmDx(安捷伦)和 SP263(VENTANA)检测用于免疫检查点抑制剂治疗的 NSCLC 患者 PD-L1 表达的试剂盒。
J Thorac Oncol. 2017 Nov;12(11):1654-1663. doi: 10.1016/j.jtho.2017.07.031. Epub 2017 Aug 14.

引用本文的文献

1
Genomic characterization of tumor mutational burden-high breast carcinomas.肿瘤突变负荷高的乳腺癌的基因组特征分析
NPJ Precis Oncol. 2025 Aug 8;9(1):277. doi: 10.1038/s41698-025-01045-x.
2
Monoclonal antibody immune therapy response instrument for stratification and cost-effective personalized approaches in 3PM-guided pan cancer management.用于在3PM引导的泛癌管理中进行分层和具有成本效益的个性化方法的单克隆抗体免疫治疗反应仪器。
EPMA J. 2025 Mar 22;16(2):465-503. doi: 10.1007/s13167-025-00403-w. eCollection 2025 Jun.
3
Comparison of PD-L1 Expression Between Preoperative Biopsy Specimens and Surgical Specimens in Non-Small Cell Lung Cancer.

本文引用的文献

1
ALK variants, PD-L1 expression, and their association with outcomes in ALK-positive NSCLC patients.ALK 变异体、PD-L1 表达及其与 ALK 阳性 NSCLC 患者结局的关系。
Sci Rep. 2020 Dec 3;10(1):21063. doi: 10.1038/s41598-020-78152-1.
2
Agreement between PDL1 immunohistochemistry assays and polymerase chain reaction in non-small cell lung cancer: CLOVER comparison study.PDL1 免疫组织化学检测与非小细胞肺癌聚合酶链反应的一致性: CLOVER 比较研究。
Sci Rep. 2020 Mar 3;10(1):3928. doi: 10.1038/s41598-020-60950-2.
3
Impact of Specimen Characteristics on PD-L1 Testing in Non-Small Cell Lung Cancer: Validation of the IASLC PD-L1 Testing Recommendations.
非小细胞肺癌术前活检标本与手术标本中PD-L1表达的比较
Cancers (Basel). 2025 Jan 25;17(3):398. doi: 10.3390/cancers17030398.
4
Programmed Cell Death Ligand 1 (PD-L1) and Major Histocompatibility Complex Class I (MHC Class I) Expression Patterns and Their Pathologic Associations in Triple-Negative Breast Cancer.程序性细胞死亡配体1(PD-L1)和主要组织相容性复合体I类(MHC I类)在三阴性乳腺癌中的表达模式及其病理相关性
Breast Cancer (Dove Med Press). 2025 Feb 6;17:123-143. doi: 10.2147/BCTT.S506833. eCollection 2025.
5
Significance of PD-L1 and Tumor Microenvironment in Laryngeal Squamous Cell Cancer.程序性死亡受体配体1(PD-L1)与肿瘤微环境在喉鳞状细胞癌中的意义
Cancers (Basel). 2024 Jul 25;16(15):2645. doi: 10.3390/cancers16152645.
6
The rapidly changing field of predictive biomarkers of non-small cell lung cancer.不断变化的非小细胞肺癌预测生物标志物领域。
Pathol Oncol Res. 2024 Jun 17;30:1611733. doi: 10.3389/pore.2024.1611733. eCollection 2024.
7
PD-L1 expression in squamous cervical carcinomas of Mozambican women living with or without HIV.莫桑比克妇女的鳞状宫颈癌中 PD-L1 的表达,无论是否感染 HIV。
Sci Rep. 2024 Jun 5;14(1):12974. doi: 10.1038/s41598-024-63595-7.
8
Comparison of SP263 and 22C3 pharmDx assays to test programmed death ligand-1 (PD-L1) expression in surgically resected non-small cell lung cancer.比较SP263和22C3免疫组化检测法在手术切除的非小细胞肺癌中检测程序性死亡配体-1(PD-L1)表达的情况。
Thorac Cancer. 2024 Jun;15(17):1343-1349. doi: 10.1111/1759-7714.15319. Epub 2024 May 3.
9
[Consistency comparison of programmed cell death 1-ligand 1 in different immuno-histochemical staining methods].[不同免疫组织化学染色方法中程序性细胞死亡蛋白1配体1的一致性比较]
Beijing Da Xue Xue Bao Yi Xue Ban. 2023 Apr 18;55(2):339-342. doi: 10.19723/j.issn.1671-167X.2023.02.020.
标本特征对非小细胞肺癌 PD-L1 检测的影响:IASLC PD-L1 检测推荐的验证。
J Thorac Oncol. 2019 Dec;14(12):2062-2070. doi: 10.1016/j.jtho.2019.08.2503. Epub 2019 Sep 5.
4
Impact of storage conditions on the quality of nucleic acids in paraffin embedded tissues.石蜡包埋组织中核酸质量的存储条件影响。
PLoS One. 2018 Sep 7;13(9):e0203608. doi: 10.1371/journal.pone.0203608. eCollection 2018.
5
Comparison of 22C3 PharmDx and SP263 Assays to Test PD-L1 Expression in NSCLC.比较22C3 PharmDx检测法和SP263检测法用于检测非小细胞肺癌中PD-L1表达的情况。
Appl Immunohistochem Mol Morphol. 2019 Oct;27(9):663-666. doi: 10.1097/PAI.0000000000000671.
6
PD-L1 Assays 22C3 and SP263 are Not Interchangeable in Non-Small Cell Lung Cancer When Considering Clinically Relevant Cutoffs: An Interclone Evaluation by Differently Trained Pathologists.PD-L1 检测试剂 22C3 和 SP263 在考虑临床相关截断值时在非小细胞肺癌中不可互换:不同培训的病理学家进行的克隆间评估。
Am J Surg Pathol. 2018 Oct;42(10):1384-1389. doi: 10.1097/PAS.0000000000001105.
7
PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project.PD-L1 免疫组织化学在真实临床样本中的可比性研究:Blueprint 阶段 2 项目的结果。
J Thorac Oncol. 2018 Sep;13(9):1302-1311. doi: 10.1016/j.jtho.2018.05.013. Epub 2018 May 22.
8
Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer.多中心协同研究:用于非小细胞肺癌的 PD-L1 IHC 检测
Ann Oncol. 2018 Apr 1;29(4):953-958. doi: 10.1093/annonc/mdy014.
9
Changes in PD-L1 expression according to tumor infiltrating lymphocytes of acquired EGFR-TKI resistant EGFR-mutant non-small-cell lung cancer.根据获得性表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKI)耐药的表皮生长因子受体(EGFR)突变非小细胞肺癌肿瘤浸润淋巴细胞情况,程序性死亡受体配体1(PD-L1)表达的变化
Oncotarget. 2017 Nov 21;8(64):107630-107639. doi: 10.18632/oncotarget.22582. eCollection 2017 Dec 8.
10
Comparison of Four PD-L1 Immunohistochemical Assays in Lung Cancer.四种 PD-L1 免疫组化检测方法在肺癌中的比较。
J Thorac Oncol. 2018 Mar;13(3):367-376. doi: 10.1016/j.jtho.2017.11.112. Epub 2017 Nov 23.